| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
|
| Targets |
Natural product; HSF1
|
|---|---|
| ln Vitro |
Azadiradione exhibits antimycobacterial and anti-inflammatory activities. It has a role as a plant metabolite, an antimycobacterial drug and an anti-inflammatory agent. It is a limonoid, a tetracyclic triterpenoid, an acetate ester, a cyclic terpene ketone and a member of furans.
|
| ln Vivo |
This study was carried out to evaluate the anti-nociceptive and anti-inflammatory activities of carbon tetrachloride extract (CTCE) of Azadirachta indica fruit skin and its isolated constituent azadiradione at two different dose levels (50 and 100 mg kg⁻¹ body weight). Anti-nociceptive screening by writhing test and hot-plate technique supported both peripheral and central mechanisms, respectively. Anti-inflammatory activity was observed using carrageenan-induced paw oedema model. The results concluded that the animals treated with 100 mg kg⁻¹ dose of CTCE and azadiradione exhibited significant anti-nociceptive and anti-inflammatory activities. This study had rationalised the ethnomedicinal use of the plant for wound, burns and injury by tribal people.[1]
This study demonstrated that partial rescue of the defective protein quality control in HD model mouse by azadiradione (a bioactive limonoids found in the seed of Azadirachta indica) could potentially improve the disease pathology. Prolonged treatment of azadiradione to HD mice significantly improved the progressive deterioration in body weight, motor functioning along with extension of lifespan. Azadiradione-treated HD mice brain also exhibited considerable decrease in mutant huntingtin aggregates load and improvement of striatal pathology in comparison with age-matched saline-treated HD controls. Biochemical analysis further revealed upregulation and activation of not only HSF1 (master regulator of protein folding) but also Ube3a (an ubiquitin ligase involved in the clearance of mutant huntingtin) in azadiradione-treated mice. Our results indicate that azadiradione-mediated enhanced folding and clearance of mutant huntingtin might underlie improved disease pathology in HD mice and suggests that it could be a potential therapeutic molecule to delay the progression of HD[2]. |
| Animal Protocol |
Transgenic mouse line for HD (strain B6CBA-Tg (HDexon1) 62Gpb/3 J) was procured from The Jackson Laboratory and bred in the animal house facility of National Brain Research Centre. This HD transgenic mouse line (commonly referred as R6/2 line) expresses Exon1 region of huntingtin with 120 CAG repeats and exhibits very fast progressive neurological phenotype [44]. Animals had free access to pelleted diet and water ad libitum. All experiments were conducted according to the strict guideline proposed by the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Ministry of Environment and Forestry, Government of India and were approved by the Institutional Animal Ethics Committee of the National Brain Research Centre (Protocol number NBRC/IAEC/2017/120). After proper genotyping, female HD mice along with their wild type littermates were used for the present study. Azadiradione was dissolved in DMSO, diluted in saline (containing 5% DMSO) and then given intraperitoneal injection (dose 10 mg/kg body weight) to wild-type and HD mice at their age of 55 days. Each mouse was received total 15 doses at 1-day interval. In some pilot experiments, wild-type mice were treated azadiradione at a dose of 1 and 10 mg/kg body weight every day for 10 days. Control mice received with same volume of saline containing 5% DMSO.[2]
|
| References |
|
| Additional Infomation |
Azadiradione is a tetracyclic triterpenoid that is 4,4,8-trimethylandrosta-1,14-diene substituted by oxo groups at positions 3 and 16, an acetoxy group at position 7 and a furan-3-yl group at position 17. Isolated from Azadirachta indica, it exhibits antimycobacterial and anti-inflammatory activities. It has a role as a plant metabolite, an antimycobacterial drug and an anti-inflammatory agent. It is a limonoid, a tetracyclic triterpenoid, an acetate ester, a cyclic terpene ketone and a member of furans.
Azadiradione has been reported in Dysoxylum parasiticum, Quivisianthe papinae, and other organisms with data available. |
| Molecular Formula |
C28H34O5
|
|---|---|
| Molecular Weight |
450.57
|
| Exact Mass |
450.241
|
| Elemental Analysis |
C, 74.64; H, 7.61; O, 17.75
|
| CAS # |
26241-51-0
|
| PubChem CID |
12308714
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
5.417
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
33
|
| Complexity |
975
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
CC(OC1CC2C(C(C=C[C@]2(C)C2CCC3(C(C4C=COC=4)C(=O)C=C3[C@]12C)C)=O)(C)C)=O
|
| InChi Key |
KWAMDQVQFVBEAU-HMWIRDDCSA-N
|
| InChi Code |
InChI=1S/C28H34O5/c1-16(29)33-23-14-20-25(2,3)22(31)8-11-26(20,4)19-7-10-27(5)21(28(19,23)6)13-18(30)24(27)17-9-12-32-15-17/h8-9,11-13,15,19-20,23-24H,7,10,14H2,1-6H3/t19-,20+,23-,24-,26-,27-,28-/m1/s1
|
| Chemical Name |
[(5R,7R,8R,9R,10R,13S,17R)-17-(furan-3-yl)-4,4,8,10,13-pentamethyl-3,16-dioxo-6,7,9,11,12,17-hexahydro-5H-cyclopenta[a]phenanthren-7-yl] acetate
|
| Synonyms |
Azadiradione; 26241-51-0; CHEBI:67280; Azadiradione (~90%); 24-Norchola-1,14,20,22-tetraene-3,16-dione, 7-(acetyloxy)-21,23-epoxy-4,4,8-trimethyl-, (5alpha,7alpha,13alpha,17alpha)-; [(5R,7R,8R,9R,10R,13S,17R)-17-(furan-3-yl)-4,4,8,10,13-pentamethyl-3,16-dioxo-6,7,9,11,12,17-hexahydro-5H-cyclopenta[a]phenanthren-7-yl] acetate; (5a,7a,13a,17a)-7-(Acetyloxy)-21,23-epoxy-4,4,8-trimethyl-24-norchola-1,14,20,22-tetraene-3,16-dione; CHEMBL1215754;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2194 mL | 11.0971 mL | 22.1941 mL | |
| 5 mM | 0.4439 mL | 2.2194 mL | 4.4388 mL | |
| 10 mM | 0.2219 mL | 1.1097 mL | 2.2194 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
